630-580-1088 sales@ambeed.com
Structure Search

List Search MOL Search Structure Search

0
Chemistry
Asymmetric Synthesis >>Chiral Building BlocksChiral Catalysts, Chiral Ligands and Chiral ReagentsChiral Resolution ReagentsBoronic acids/esters >>Aliphatic BoronsAromatic BoronsOther BoronsOxaborolesCatalysis Chemistry >>Achiral Crown LigandsC-H ActivationCarbon-Donor LigandsChiral Carbon LigandsChiral Crown LigandsChiral Olefin LigandsCross-CouplingCross-Coupling Using Transition Metal CatalystsDACH or Trost LigandsChemical Biology >>Conjugation Chemistry
GlycoscienceLinkers and CrosslinkersNucleic Acid ChemistryPEGylationPeptide ChemistryPhotolabile Protecting GroupHeterocyclic Building Blocks >>AcridinesAliphatic HeterocyclesAromatic HeterocyclesAzetidinesBenzimidazolesBenzisoxazolesBenzodioxansBenzofuransBenzothiazolesInorganic reagents >>Inorganic ReagentOrganic Building Blocks >>Acid AnhydridesAcyl Chlorides
AlcoholsAldehydesAliphatic Chain HydrocarbonsAliphatic Cyclic HydrocarbonsAlkenesAlkylsAlkynesOrganometallic Reagents >>Grignard ReagentsOrganoarsenicOrganobismuthOrganoboronOrganogermaniumOrganolithiumOrganomercuryOrganosiliconOrganotinSpecialty Synthesis >>Enzyme-Mediated SynthesisFluorous SynthesisIonic Liquids
Solid Supported SynthesisStains and Dyes >>Acid DyesAzoic DyesBasic DyesDirect DyesDisperse DyesDye IntermediatesMordant DyesOil DyesOther Stains and DyesSynthetic Reagents >>Acids and BasesC-C Bond FormationC-X Bond Formation (Halogen)C-X Bond Formation (Non-Halogen)Chelation and Complexation CompoundsCondensation AgentsCouplingDehydrating ReagentsFluorination Reagent
Pharmaceutical Intermediates
Analgesics >>BenzhydrocodoneBicifadineCapsaicinCelecoxibDebio-0827DexamethasoneElagolix SodiumEsketamine HydrochlorideIbuprofen SodiumAnesthetics >>CiprofolEsketamine HydrochlorideFospropofol Fospropofol DisodiumLevobupivacaine RemimazolamRemimazolam BesilateRemimazolam BesylateRopivacaineAnti-Addiction Agents >>Kakonein
Lofexidine HydrochlorideVarenicline Anti-inflammatory Agents >>ApremilastAsunaprevirATB-346 RelatedBalsalazide BaricitinibBencycloquidium BromideBudesonideCefiderocol Sulfate TosylateCeftaroline Fosamil AcetateAntibacterials >>AFN-1252 RelatedAlatrofloxacin Bedaquiline FumarateBesifloxacin BrilacidinCaspofungin AcetateCefiderocol Sulfate TosylateCefilavancinCeftaroline Fosamil
Anticonvulsants >>BrivaracetamCannabidiolEscitalopram OxalateEslicarbazepine Acetate RelatedFosphenytoinGabapentin EnacarbilJNJ-10234094LacosamideLevetiracetam RelatedAntidementia Agents >>Azeliragon RelatedDavunetideDonepezil HydrochlorideDonepezil RelatedEnsaculinFlorbetaben Flortaucipir F 18Flutemetamol IdalopirdineAntidepressants >>4-Chlorokynurenine
AgomelatineAgomelatine RelatedAllopregnanolone RelatedAmibegronAmitifadineAripiprazole RelatedBasimglurantBefloxatoneAntiemetics >>AprepitantAprepitant RelatedDolasetron RelatedDolasetron Mesylate HydrateFosaprepitant DimeglumineFosaprepitant RelatedOlanzapinePalonosetron RelatedPalonosetron HydrochlorideAntifungals >>Anidulafungin RelatedCabotegravirMore >>
Inhibitors/Agonists
ADC >>ADC AntibodyADC LinkerADC Linker with PayloadADC ToxinAntibody-Drug Conjugates (ADCs)Drug-Linker Conjugates for ADCAngiogenesis >>ALKBcr-AblBTKEGFRFAKFGFRFLT3HER2HIFAnti-infection >>3CLproAntibacterialAntibioticAntifungal
AntiparasiticAntiprotozoalAntiviralArenavirusBVDVApoptosis >>Apoptosis InducerBcl-2Bcl-6BRKc-Mycc-RETC/EBPCARDCaspaseAutophagy >>Atg4ATG4BATTECsAUTACsAutophagyBeclin1
FKBPLC3LRRK2Biochemical Reagent >>Cell Cycle >>AntifolateAPCAurora KinaseBUBCasein KinaseCdc25CDKChkCRISPR/Cas9Cytoskeleton >>ActinArp2/3 ComplexCYTHCytoplasmic DyneinDynaminFAKMore >>
Material Science
Aggregation-Induced Emission >>Other AIE BlocksTetraphenylethylene SeriesCOFs Linkers >>Aldehyde COFs LinkersAlkynyl COFs LinkersAmine COFs LinkersBoric COFs LinkersCyano COFs LinkersMultifunctional COFs linkersOther COFs linkersTriptycene SeriesElectronic Materials >>Battery MaterialsDye-Sensitized Solar Cell (DSSC) MaterialsElectronic MaterialLiquid Crystal (LC) MaterialsMolecular ConductorsOrganic Light-Emitting Diode (OLED) MaterialsOrganic Solar Cell (OPV) MaterialsOrganic Transistor (OFET) MaterialsPerovskite Solar Cell (PSC) MaterialsMagnetic Materials >>Magnetic Ionic LiquidsMagnetic MaterialMagnetic Metal Complexes
Organic Radicals Material Chemical Compounds >>Ligands for Functional Metal ComplexesLiquid Crystal (LC) Building BlocksPhthalocyanine Building BlocksPolymer and Macromolecule Semiconductor Building BlocksSmall Molecule Semiconductor Building BlocksSolubility Enhancing Reagents Supramolecular Host Materials MOF Ligands >>Carboxylic Acid MOF LigandsCarboxylic Acid Nitrogen-Containing Mixed MOF LigandsNitrogen-Containing MOF LigandsOther MOF LigandsNanomaterials >>Carbon NanomaterialsCeramic MembranesDendrimersGold NanoparticlesIron Oxide NanoparticlesMaterials by ApplicationMesoporous MaterialsMetals and Metal AlloysNano Minerals: NanoclaysOLED Materials >>Dopant
HostHTMOLED IntermediatesOther OLED related materialsOptical Materials >>Coumarin DyesCyanine and Squarylium DyesDCM DyesDipyrromethene DyesFluorescence MaterialsFluorescent ProbesHeat and Pressure Sensitive DyesNear-Infrared (NIR) DyesOrganic Non-Linear Optical (NLO) MaterialsOrganic Pigments >>Organic PigmentOther Materials >>Mateial OtherPolymer Science >>MonomersPolymer AdditivesPolymerization ReagentsPolymersResins
Contact Us
Home Cart 0 Sign in  
Chemistry
Organic Building Blocks
Aryls
benzyl
(4-(tert-Butyl)phenyl)hydrazine xhydrochloride
Chemistry
Organic Building Blocks
Aryls
Amines Hydrazines Benzene Compounds
benzyl
tert-butylbenzene phenylhydrazine

[ CAS No. 36600-66-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 36600-66-5
Chemical Structure| 36600-66-5
Structure of 36600-66-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 36600-66-5 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 36600-66-5 ]

SDS Specification
Alternatived Products of [ 36600-66-5 ]

Product Details of [ 36600-66-5 ]

CAS No. :36600-66-5 MDL No. :MFCD00013387
Formula : C10H17ClN2 Boiling Point : -
Linear Structure Formula :- InChI Key :VTESCYNPUGSWKG-UHFFFAOYSA-N
M.W : 200.71 Pubchem ID :16217458
Synonyms :

Safety of [ 36600-66-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 36600-66-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 36600-66-5 ]

[ 36600-66-5 ] Synthesis Path-Downstream   1~88

  • 1
  • [ 7530-37-2 ]
  • [ 36600-66-5 ]
  • [ 136282-06-9 ]
Reference： [1]Tetrahedron,1991,vol. 47,p. 4383 - 4408
  • 2
  • [ 36600-66-5 ]
  • [ 83-33-0 ]
  • [ 133587-48-1 ]
Reference： [1]Tetrahedron,1991,vol. 47,p. 4383 - 4408
  • 3
  • [ 36600-66-5 ]
  • [ 615-13-4 ]
  • [ 136282-05-8 ]
  • [ 136282-19-4 ]
Reference： [1]Tetrahedron,1991,vol. 47,p. 4383 - 4408
  • 4
  • [ 13865-88-8 ]
  • [ 36600-66-5 ]
  • 10-tert-Butyl-2-methoxy-7H-estra-1,3,4a(14a)-trieno[17,16-b]indole [ No CAS ]
Reference： [1]Journal of the Chemical Society. Perkin transactions I,1997,p. 2329 - 2336
  • 5
  • [ 36600-66-5 ]
  • 3α-Hydroxy-5α-androstan-17-one [ No CAS ]
  • (3R,5S,8S,9S,10S,13S,14S)-17-[(4-tert-Butyl-phenyl)-hydrazono]-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-ol [ No CAS ]
Reference： [1]Journal of the Chemical Society. Perkin transactions I,1997,p. 2329 - 2336
  • 6
  • [ 36600-66-5 ]
  • [ 94-05-3 ]
  • [ 203123-01-7 ]
Reference： [1]Journal of Heterocyclic Chemistry,1997,vol. 34,p. 1693 - 1697
  • 7
  • [ 648869-31-2 ]
  • [ 326-56-7 ]
  • [ 36600-66-5 ]
  • 3-[5-benzo[1,3]dioxol-5-yl-1-(4-<i>tert</i>-butyl-phenyl)-1<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[5-benzo[1,3]dioxol-5-yl-2-(4-<i>tert</i>-butyl-phenyl)-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 8
  • [ 648869-33-4 ]
  • [ 326-56-7 ]
  • [ 36600-66-5 ]
  • 3-[5-benzo[1,3]dioxol-5-yl-1-(4-<i>tert</i>-butyl-phenyl)-1<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[5-benzo[1,3]dioxol-5-yl-2-(4-<i>tert</i>-butyl-phenyl)-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 9
  • [ 648869-31-2 ]
  • [ 2905-65-9 ]
  • [ 36600-66-5 ]
  • 3-[2-(4-<i>tert</i>-butyl-phenyl)-5-(3-chloro-phenyl)-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[1-(4-<i>tert</i>-butyl-phenyl)-5-(3-chloro-phenyl)-1<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 10
  • [ 648869-33-4 ]
  • [ 2905-65-9 ]
  • [ 36600-66-5 ]
  • 3-[2-(4-<i>tert</i>-butyl-phenyl)-5-(3-chloro-phenyl)-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[1-(4-<i>tert</i>-butyl-phenyl)-5-(3-chloro-phenyl)-1<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 11
  • [ 648869-31-2 ]
  • [ 2459-25-8 ]
  • [ 36600-66-5 ]
  • 3-[2-(4-<i>tert</i>-butyl-phenyl)-5-naphthalen-2-yl-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[1-(4-<i>tert</i>-butyl-phenyl)-5-naphthalen-2-yl-1<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 12
  • [ 648869-33-4 ]
  • [ 2459-25-8 ]
  • [ 36600-66-5 ]
  • 3-[2-(4-<i>tert</i>-butyl-phenyl)-5-naphthalen-2-yl-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[1-(4-<i>tert</i>-butyl-phenyl)-5-naphthalen-2-yl-1<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 13
  • [ 648869-31-2 ]
  • [ 21218-94-0 ]
  • [ 36600-66-5 ]
  • 3-[2-(4-<i>tert</i>-butyl-phenyl)-5-(4-phenoxy-phenyl)-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[1-(4-tert-Butyl-phenyl)-5-(4-phenoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 14
  • [ 648869-33-4 ]
  • [ 21218-94-0 ]
  • [ 36600-66-5 ]
  • 3-[2-(4-<i>tert</i>-butyl-phenyl)-5-(4-phenoxy-phenyl)-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[1-(4-tert-Butyl-phenyl)-5-(4-phenoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 15
  • [ 648869-31-2 ]
  • [ 2905-68-2 ]
  • [ 36600-66-5 ]
  • 3-[2-(4-<i>tert</i>-butyl-phenyl)-5-(3,4-dichloro-phenyl)-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[1-(4-<i>tert</i>-butyl-phenyl)-5-(3,4-dichloro-phenyl)-1<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 16
  • [ 648869-33-4 ]
  • [ 2905-68-2 ]
  • [ 36600-66-5 ]
  • 3-[2-(4-<i>tert</i>-butyl-phenyl)-5-(3,4-dichloro-phenyl)-2<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
  • 3-[1-(4-<i>tert</i>-butyl-phenyl)-5-(3,4-dichloro-phenyl)-1<i>H</i>-pyrazol-3-yl]-2-<i>m</i>-tolyl-propionic acid [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 77 - 80
  • 17
  • 6-Hydroxy-1-(3-pyridinyl)-hexan-1,3-dione [ No CAS ]
  • [ 27784-76-5 ]
  • [ 36600-66-5 ]
  • C27H33N3O2 [ No CAS ]
  • C27H33N3O2 [ No CAS ]
Reference： [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 2080 - 2085
  • 18
  • [ 36600-66-5 ]
  • 2-(4-<i>tert</i>-butyl-phenyl)-1-oxy-2,4-dihydro-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidine-5,7-dione [ No CAS ]
Reference： [1]Chemistry of Heterocyclic Compounds,2004,vol. 40,p. 361 - 363
  • 19
  • [ 36600-66-5 ]
  • 6-benzoyl-5'-tert-butyl-1'-methyl-3,5-diphenyldispiro[cyclohexa-2,4-diene-1,2'-indoline-3',1"-cyclohexane] [ No CAS ]
Reference： [1]Journal of Heterocyclic Chemistry,2002,vol. 39,p. 255 - 262
  • 20
  • [ 36600-66-5 ]
  • 5'-tert-butyl-1',2'-dimethylspiro[cyclohexane-1,3'-indolium] perchlorate [ No CAS ]
Reference： [1]Journal of Heterocyclic Chemistry,2002,vol. 39,p. 255 - 262
  • 21
  • [ 36600-66-5 ]
  • 2-tert-butyl-10,10-dimethyl-6,8-diphenyl-10H-pyrido[1,2-a]indolium perchlorate [ No CAS ]
Reference： [1]Journal of Heterocyclic Chemistry,2002,vol. 39,p. 263 - 269
  • 22
  • [ 36600-66-5 ]
  • 4-{<i>N</i>'-[3-amino-1-(4-<i>tert</i>-butyl-phenyl)-5-oxo-1,5-dihydro-pyrazol-4-ylidene]-hydrazino}-3-hydroxy-naphthalene-1-sulfonic acid [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,2001,vol. 44,p. 3730 - 3745
  • 23
  • [ 36600-66-5 ]
  • [ 222733-86-0 ]
Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 526 - 531
  • 24
  • [ 36600-66-5 ]
  • 5-(t-butyl)-N-methyltryptamine [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 526 - 531
  • 25
  • [ 36600-66-5 ]
  • [2-(5-<i>tert</i>-butyl-1<i>H</i>-indol-3-yl)-ethyl]-dimethyl-amine [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 526 - 531
  • 26
  • [ 36600-66-5 ]
  • [2-(5-<i>tert</i>-butyl-1<i>H</i>-indol-3-yl)-ethyl]-propyl-amine [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 526 - 531
  • 27
  • [ 36600-66-5 ]
  • tert-butyl 2-(5-tert-butyl-1H-indol-3-yl)ethyl-carbamate [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 526 - 531
  • 28
  • [ 36600-66-5 ]
  • [2-(5-<i>tert</i>-butyl-1<i>H</i>-indol-3-yl)-ethyl]-dipropyl-amine [ No CAS ]
Reference： [1]Journal of Medicinal Chemistry,1999,vol. 42,p. 526 - 531
  • 29
  • [ 36600-66-5 ]
  • 7-(4-tert-Butyl-phenyl)-1-methyl-2,2-dioxo-1,2,3,7-tetrahydro-2λ6-pyrazolo[3,4-c][1,2]thiazin-4-one [ No CAS ]
Reference： [1]Journal of Heterocyclic Chemistry,1997,vol. 34,p. 1693 - 1697
  • 30
  • [ 36600-66-5 ]
  • [ 203123-09-5 ]
Reference： [1]Journal of Heterocyclic Chemistry,1997,vol. 34,p. 1693 - 1697
  • 31
  • [ 36600-66-5 ]
  • [ 203123-15-3 ]
Reference： [1]Journal of Heterocyclic Chemistry,1997,vol. 34,p. 1693 - 1697
  • 32
  • [ 36600-66-5 ]
  • [ 203123-03-9 ]
Reference： [1]Journal of Heterocyclic Chemistry,1997,vol. 34,p. 1693 - 1697
  • 33
  • [ 36600-66-5 ]
  • 2α-Acetoxy-10-tert-butyl-7H-(14α-androstano[17,16-b]indole) [ No CAS ]
Reference： [1]Journal of the Chemical Society. Perkin transactions I,1997,p. 2329 - 2336
  • 34
  • [ 36600-66-5 ]
  • 10-tert-Butyl-6b,11b-dihydro-2-methoxy-7H-estra-1,3,4a(14a)-trieno[17,16-b]indole [ No CAS ]
Reference： [1]Journal of the Chemical Society. Perkin transactions I,1997,p. 2329 - 2336
  • 35
  • [ 36600-66-5 ]
  • anti-2α-Acetoxy-10-tert-butyl-6b,11b-dihydro-7H-(14α-androstano[17,16-b]indole) [ No CAS ]
Reference： [1]Journal of the Chemical Society. Perkin transactions I,1997,p. 2329 - 2336
  • 36
  • [ 36600-66-5 ]
  • [ 133571-85-4 ]
Reference： [1]Tetrahedron,1991,vol. 47,p. 4383 - 4408
  • 37
  • [ 36600-66-5 ]
  • [ 133571-58-1 ]
Reference： [1]Tetrahedron,1991,vol. 47,p. 4383 - 4408
  • 38
  • [ 36600-66-5 ]
  • [ 133571-84-3 ]
Reference： [1]Tetrahedron,1991,vol. 47,p. 4383 - 4408
  • 39
  • [ 36600-66-5 ]
  • Lithium; (4bR,9bS)-8-tert-butyl-9b,10-dihydro-4bH-indeno[1,2-b]indole-5-carboxylate [ No CAS ]
Reference： [1]Tetrahedron,1991,vol. 47,p. 4383 - 4408
  • 40
  • [ 142314-70-3 ]
  • [ 36600-66-5 ]
  • [ 846055-77-4 ]
YieldReaction ConditionsOperation in experiment
In 1,4-dioxane; acetic acid; at 200℃; for 0.333333h;Microwave irradiation; A solution of the aldehyde (Step C, 0.58 g, 3.3 mmol), 4-t-butylphenylhydrazine-HCl (0.66 g, 3.3 mmol), AcOH (1 mL), and dioxane (3 mL) in a sealed reaction vial was heated at 200° C. for 20 min in a microwave. Upon cooling, the residue was diluted with EtOAc (10 mL), then hexane (10 mL). The resulting precipitate was filtered to afford the desired compound as a tan solid. MS m/e 324 (M+H)+. Calc'd for C18H17N3O3- 323.35.
Reference： [1]Patent: US2005/49253,2005,A1 .Location in patent: Page/Page column 26
  • 41
  • [ 59997-51-2 ]
  • [ 36600-66-5 ]
  • [ 905589-38-0 ]
YieldReaction ConditionsOperation in experiment
In methanol; ethyl acetate; (1) A solution of pivaloylacetonitrile (4.60 g) and <strong>[36600-66-5]4-tert-butylphenylhydrazine hydrochloride</strong> (3.167 g) in a mixed solvent of ethyl acetate (63 mL) and methanol (7 mL) was heated under reflux for 12 hr. The solvent of the reaction mixture was evaporated, and the residue was poured into ethyl acetate. The mixture was washed with saturated aqueous sodium hydrogencarbonate solution and saturated brine, and dried, and the solvent was evaporated. The residue was purified by column chromatography to give 3-tert-butyl-1-(4-tert-butylphenyl)-1H-pyrazol-5-amine (3.54 g). 1H-NMR (300 MHz, CDCl3) deltappm 1.21 (9 H, s) 1.31 (9 H, s) 5.15 (2 H, br s) 5.36 (1 H, s) 7.46 (4 H, m)
Reference： [1]Patent: WO2006/82952,2006,A1 .Location in patent: Page/Page column 208-209
[2]Patent: EP1845081,2007,A1
  • 42
  • [ 36600-66-5 ]
  • [ 75-36-5 ]
  • [ 76-05-1 ]
  • [ 460746-46-7 ]
  • [ 460748-72-5 ]
YieldReaction ConditionsOperation in experiment
4% With formic acid; tin(IV) chloride; In methanol; dichloromethane; acetonitrile; Example 159 4-(3-acetyl-2-{2-[(2R)-2-methyl-1-pyrrolidinyl]ethyl}-1-benzofuran-5-yl)benzonitrile The product of Example 1D (330 mg, 1.0 mmol) was dissolved into CH2Cl2 (500 muL) and cooled to 0° C. Acetyl chloride (140 muL, 2.0 mmol) and 1 M SnCl4 in CH2Cl2 (1.5 mL, 1.5 mmol) were added, the reaction was permitted to warm to room temperature and it was stirred overnight. The mixture was partitioned between 20percent EtOAc/CH2Cl2 and 0.5 M aqueous dipotassium hydrogen phosphate. The aqueous phase and solids were separated and extracted with CH2Cl2, and the organic phases were combined and worked up as usual but with an aqueous dipotassium hydrogen phosphate wash, dried (Na2SO4), and concentrated. The residue was then resubjected to the same reaction conditions used previously except with additional CH2Cl2 (7 mL), stirred for five days, and worked up as before. The concentrated residue was chromatographed through silica (MeOH/EtOAc/CH2Cl2) to afford an inseparable mixture of product and starting material. The mixture (260 mg) and <strong>[36600-66-5](4-tert-butylphenyl)-hydrazine hydrochloride</strong> (201 mg, 1.0 mmol) were dissolved into methanol (2 mL) and treated with 88percent aqueous formic acid. The mixture was stirred overnight, concentrated, partitioned between 0.5 M dipotassium hydrogen phosphate and CH2Cl2, worked up as usual, dried (Na2SO4), concentrated, and chromatographed through silica with a gradient of 0.5 to 4percent MeOH in 20percent MECN/CH2Cl2. The appropriate fractions were concentrated, and after a few days appeared to have decomposed, partially to the desired ketone. The residue was rechromatographed through a short column of silica with a gradient of 0 to 4percent MeOH/CH2Cl2, and then purified by HPLC [Waters Nova-Pak HR C18 column (40 mm*100 mm, 6 mum particle size) using a gradient of 10percent to 100percent MeCN/0.1percent aqueous TFA over 12 min (15 min run time) at a flow rate of 70 mL/min.] to provide the title compound (4percent yield). MS (ESI APCI) m/z 373 (M+H)+; 1H-NMR (300 MHz, CD3OD) delta 1.49 (d, 3H), 1.68-1.84 (m, 1H), 2.01-2.25 (m, 2H), 2.31-2.46 (m, 1H), 2.80 (s, 3H), 3.3-3.71 (m, 5H), 3.76-3.92 (m, 2H), 7.69-7.76 (m, 2H), 7.84 (d, 2H), 7.89 (d, 2H), 8.20-8.22 (m, 1H).
Reference： [1]Patent: US2002/169188,2002,A1
  • 43
  • N-(3-[1-(4-tert-butylphenyl)-5-pyridin-3-yl-1H-pyrazol-3-yl]propanoyl)tyrosinamide [ No CAS ]
  • [ 36600-66-5 ]
  • N-(3-[1-(4-tert-butylphenyl)-3-pyridin-3-yl-1H-pyrazol-5-yl]propanoyl)tyrosinamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
In methanol; Compound 3-B: 3-{1-(4-tert-butylphenyl)-5-pyridin-3-yl-1H-pyrazol-3-yl}propan-1-ol and 3-{1-(4-tert-butylphenyl)-3-pyridin-3-yl-1H-pyrazol-5-yl}propan-1-ol. A solution of compound 3-A (370 mg, 1.79 mmol) and <strong>[36600-66-5]4-tert-butylphenylhydrazine hydrochloride</strong> (359 mg, 1.79 mmol) in absolute methanol (10 mL) was stirred overnight at 25° C. The reaction mixture was then adsorbed on silica gel (5 g) and purified by flash chromatography on silica gel (60 g), eluding with DCM/MeOH/NH4OH (96/4/1), to afford 709 mg of a yellow oil containing the pyrazole 3-B (two regioisomers, 452 mg, 75percent, ratio 24/76) and DMSO. An aliquot of this mixture was purified with preparative HPLC deltapack C18 column, using a gradient of water/acetonitrile from 95/5 to 50/50 in 60 min, to give pure samples of the two regioisomers. More Polar Regioisomer 1H NMR (CDCl3): delta 8.80 (s, 1H), 8.76 (d, J=5.0 Hz, 1H), 7.95 (d, J=8.1), 7.70 (dd, J=8.1, 5.4 Hz, 1H), 7.43 (d, J=7.7 Hz, 2H), 7.16 (d, J=8.1Hz, 2H),6.60 (s, 1H), 4.48 (t, J=6.0 Hz, 2H), 2.88 (t, J=7.3Hz, 2H), 2.23(pent., J=7.0 Hz, 2H), 1.32 (s, 9H). MS (ESI,+): 336 (M+1)
Reference： [1]Patent: US2002/132844,2002,A1
  • 44
  • [ 36600-66-5 ]
  • [ 128230-98-8 ]
  • [ 128231-13-0 ]
YieldReaction ConditionsOperation in experiment
83% EXAMPLE 24 5-(3,6-Dihydro-6-methyl-2-oxo-2H-1,3,4-thiadiazin-5-yl) -1H-indole-2,3-dione 3-[4-(1,1-dimethylethyl) phenylhydrazone] STR45 Starting from 1,3-dihydro-5-(3,6-dihydro-6-methyl-2-oxo -2H-1,3,4-thiadiazin-5-yl)-3-phenylimino-2H-indol-2-one, and 4t-butyl phenylhydrazine hydrochloride and following the method described in Example 21, the desired compound was obtained. Yield: 83percent m.p.: 299° C. IR (KBr): upsilon=3,200; 1,680; 1,635; 1,615; 1,550; 1,180 cm-1. NMR (DMSO-d6): delta=1.29 (s,9H,t-Bu); 1.50(d,J=7.1 Hz,3H, CH3CH); 4.82 (q,J=7.1 Hz,1H,CH3CH); 7.00 (d,J=8.3 Hz,1H, Ar); 7.41 (s,4H,ArtBu); 7.72 (d,J=8.3 Hz,1H,Ar); 7.99 (s,1H,Ar); 11.26 (s,1H,exch.D2 O,NH); 11.66 (s,1H,exch. D2 O,NH); 12.77 (s,1H,exch.D2 O,NH).
Reference： [1]Patent: US5051417,1991,A
  • 45
  • [ 36600-66-5 ]
  • [ 551-93-9 ]
  • [ 917966-92-8 ]
YieldReaction ConditionsOperation in experiment
Example 54; 1-(2-(5-tert-butyl-1H-indol-2-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea; 54a. 2-(5-tert-butyl-1H-indol-2-yl)aniline; 2-aminoacetophenone (1 g, 7.4 mmol), 4-tertbutylphenylhydrazine hydrochloride (1.48g, 7.4 mmol) and acetic acid (0.5 mL) were added to EtOH (25 mL) and refluxed for 30 min. The mixture was evaporated in vacuo. Methanesulfonic acid (17 mL) and phosphorus pentoxide (2.2 g, 15.5 mmol) were added and the mixture was heated at 80° C. for 2 h. The reaction mixture was poured over crushed ice and basified using sodium hydroxide pellets. The solid formed was isolated by filtration, washed with water and air dried to yield the desired material (4.45 g, directly used in the next step without further purification).
Reference： [1]Patent: US2006/293336,2006,A1 .Location in patent: Page/Page column 42
  • 46
  • [ 36600-66-5 ]
  • [ 138163-08-3 ]
  • [ 918421-64-4 ]
YieldReaction ConditionsOperation in experiment
51% To a flask under N2 containing 4-^butylphenylhydrazine hydrochloride (1.0 g, 5 mmol) in degassed toluene/CH3CN (50/1, 22 mL) and TFA (1.5 g, 13 mmol) was added 1- ben2yloxycarbonyl-piperidine-4-carbaldehyde (1.2 g, 5 mmol) at room temperature. After stirring for 15 min, the reaction was heated to 400C and stirred overnight. The reaction was cooled to 50C, and MeOH (27 mL) was added and followed by NaBH4 (0.25 g, 6.7 mmol). The reaction was stirred for an additional 1 h, diluted with EtOAc (60 mL), and washed with IN NaOH (2x) and brine. The organic layer was dried with anhydrous MgSO4 and concentrated to afford solid residue, which was washed with hexane/ether (5/1) several times to give 1.0 g (51 percent) of 1'- (benzyloxycarbonyl)- 1 ,2-dihydro-5 -^-buryl-spiro [3H-indole-3 ,4 ' -piperidine] . LC-MS m/z 379 (M + H)+; 1H NMR (400 MHz, DMSO-fe) delta 7.39-7.31 (m, 5 H), 7.01 (s, 1 H), 6.93 (d, 1 H, J= 7.8 Hz), 6.41 (d, 1 H, J= 7.8 Hz), 5.34 (s, 1 H), 5.10 (s, 2 H), 3.98 (bd, 2 H, J= 13 Hz), 3.37 (s, 2 H), 2.98 (bm, 2 H), 1.71-1.55 (m, 4 H), 1.21 (s, 9 H).
Reference： [1]Patent: WO2007/2114,2007,A1 .Location in patent: Page/Page column 56
  • 47
  • [ 1003869-42-8 ]
  • [ 36600-66-5 ]
  • [ 1003869-43-9 ]
Reference： [1]Journal of Medicinal Chemistry,2008,vol. 51,p. 659 - 665
  • 48
  • [ 36600-66-5 ]
  • [ 252894-39-6 ]
  • [ 1003869-22-4 ]
Reference： [1]Journal of Medicinal Chemistry,2008,vol. 51,p. 659 - 665
  • 49
  • [ 36600-66-5 ]
  • [ 141-97-9 ]
  • [ 681427-09-8 ]
YieldReaction ConditionsOperation in experiment
78% In acetic acid; at 100℃; for 22h; (1) 1-(4-t-Phenyl)-5-hydroxy-3-methyl-1H-pyrazole 4-t-Butylphenylhydrazine hydrochloride (24.2 g, 120 mmol) in acetic acid (600 mL) was stirred with ethyl acetoacetate (16.4 mL, 129 mmol) at 100°C for 22 hours. The solvent was removed by distillation under reduced pressure, and the resulting solid was recrystallized from chloroform (70 ml, 40°C)-diethyl ether (200 mL, 0°C), washed with diethyl ether and dried under reduced pressure to give 21.7 g of the desired product (78percent yield). Morphology: colorless solid LC/MS: Condition 2, retention time 3.52 (min) LC/MS (ESI+) m/z; 231 [M+1]
69% With acetic acid; at 110℃; for 6h; Example 2; Preparation of 4-[2-(3-cyclohexyl-2-hydroxyphenyl)hydrazin-1-ylidene]-1-(4-tert-butylphenyl)-3-methyl-4,5-dihydro-]H-pyrazol-5-one; Step 1:; Compound 2a (1-<strong>[36600-66-5][4-(tert-butyl)phenyl]hydrazine hydrochloride</strong>, Maybridge Catalog Number BTB08670EA) (2.0 g, 10.0 mmol) and ethyl acetoacetate (1.95 g, 15.0 mmol) were heated in acetic acid (20 mL) to reflux at an oil bath temperature of 110 deg C. for 6 hours. The amber solution was allowed to cool, and the solvent was removed under reduced pressure. The residue was suspended in 40percent ethyl acetate-hexanes (25 mL) and allowed to stir for 1 h. The resulting precipitate was filtered and washed with 40percent ethyl acetate-hexanes to afford Compound 2b as a white powder (1.58 g, 69percent) (i.e., Example compound 4(a) in PCT International Patent Publication No. WO2001/089457 A2, herein incorporated by reference in its entirety).
Reference： [1]Patent: EP2025671,2009,A1 .Location in patent: Page/Page column 49
[2]Patent: US2008/139621,2008,A1 .Location in patent: Page/Page column 37
  • 50
  • [ 1203608-45-0 ]
  • [ 36600-66-5 ]
  • 5-(2-bromophenyl)-1-(4-tert-butyl-phenyl)-1H-pyrazole [ No CAS ]
Reference： [1]Journal of Organic Chemistry,2010,vol. 75,p. 434 - 441
  • 51
  • [ 1203608-46-1 ]
  • [ 36600-66-5 ]
  • [ 1203608-53-0 ]
Reference： [1]Journal of Organic Chemistry,2010,vol. 75,p. 434 - 441
  • 52
  • [ 532-24-1 ]
  • [ 36600-66-5 ]
  • [ 1220278-98-7 ]
YieldReaction ConditionsOperation in experiment
A suspension of (4-ter.pound.-butylphenyl)hydrazine hydrochloride (1000 mg, 5.0 mmol;Aldrich), tropinone (696 mg, 5.0 mmol; Aldrich), and 4 M HCl-dioxane (2.5 mL, 10.0 mmol; Aldrich) in ethanol (10 mL) was heated to 80 °C for 16 hours. After cooling to room temperature, the reaction mixture was concentrated, basified with 5 NNaOH (aqueous), and then extracted with ethyl acetate (3x50 mL). The combined organic phase was concentrated and the residue was purified by reverse-phase HPLC [Waters XBridge.(TM). RP 18 column, 5 mum, 30x100 mm, flow rate 40 mL/minute, 20-95percent gradient of methanol in buffer (0.1 M aqueous ammonium bicarbonate, adjusted to pH 10 with ammonium hydroxide)] to afford the title compound: 1H NMR (300 MHz, methanol-^) delta ppm 1.36 (s, 9 H), 1.61 - 1.74 (m, 1 H), 1.93 (t, J=9 Hz, 1 H), 2.25 - 2.36 (m, 2 H), 2.41 (s, 3 H), 2.48 (d, J=17 Hz, 1 H), 3.21 - 3.29 (m, 1 H), 3.56 - 3.63 (m, 1 H), 4.26 (d, J=4 Hz, 1 H), 7.10 - 7.15 (m, 1 H), 7.16 - 7.21 (m, 1 H), 7.38 (d, J=I Hz, 1 H); MS (DCI/NH3) m/z 269 (M+H)+.
Reference： [1]Patent: WO2010/36998,2010,A2 .Location in patent: Page/Page column 155
  • 53
  • [ 85302-07-4 ]
  • [ 36600-66-5 ]
  • [ 1203661-42-0 ]
Reference： [1]Journal of Medicinal Chemistry,2010,vol. 53,p. 649 - 659
  • 54
  • [ 36600-66-5 ]
  • [ 34737-83-2 ]
  • 8-tert-butoxy-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole [ No CAS ]
YieldReaction ConditionsOperation in experiment
Example 15A [0419] (4-te/t-Butylphenyl)hydrazine hydrochloride (I g, 4.98 mmol) was dissolved in 7percent H2SO4 in 1,4-dioxane (50 mL), l-methylpiperidin-4-1 hydrochloride (0.742 g, 4.98 mmol) was added and stirred at 80 0C for 3 h. Reaction was monitored by TLC LCMS. After completion of the reaction, reaction mixture was concentrated under vacuum and quenched with aq. NaHCO3 solution, extracted with EtOAc. Organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum and purified by column chromatography (5percent Methanol- DCM) to afford 0.51 g of 8-tert-butoxy-2-methyl-2,3,4,5-tetrahydro-lH-pyrido[4,3-b]indole. 1H NMR (DMSO-J6, free base) d (ppm) 11.1 (bs,lH), 10.6 (bs, IH), 7.4 (s, IH), 7.3-7.2 (d,lH), 7.2-7.1 (d, IH), 4.6-4.5 (m, IH), 4.3 (bs, IH), 3.7 (bs, IH), 3.5 (bs, IH), 3.2-3.3 (m, 2H), 2.9 (s, 3H),1.3 (s, 9H).
Reference： [1]Patent: WO2010/51501,2010,A1 .Location in patent: Page/Page column 241-242
  • 55
  • [ 36600-66-5 ]
  • [ 94-02-0 ]
  • [ 1257976-34-3 ]
Reference： [1]Bioorganic and Medicinal Chemistry,2010,vol. 18,p. 7849 - 7854
  • 56
  • [ 39755-95-8 ]
  • [ 36600-66-5 ]
  • [ 1263428-98-3 ]
YieldReaction ConditionsOperation in experiment
77% In methanol; at 20℃; General procedure: Suitable indoline-2,3-dione 1a-c (1.0 mmol) was dissolved in methanol (5 mL) with gentle heating, then arylhydrazine (2.4 mmol) was slowly added with stirring at room temperature. After stirring overnight, the resulting precipitate was filtered and crystallized or the reaction mixture was evaporated to dryness and the residue suitably purified.
Reference： [1]European Journal of Medicinal Chemistry,2011,vol. 46,p. 275 - 284
  • 57
  • [ 1445-73-4 ]
  • [ 36600-66-5 ]
  • [ 1147938-68-8 ]
Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 639 - 651
  • 58
  • [ 36600-66-5 ]
  • [ 1354547-24-2 ]
Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 639 - 651
  • 59
  • [ 36600-66-5 ]
  • [ 1354547-12-8 ]
Reference： [1]Journal of Medicinal Chemistry,2012,vol. 55,p. 639 - 651
  • 60
  • [ 21352-99-8 ]
  • [ 36600-66-5 ]
  • [ 1409944-83-7 ]
Reference： [1]Synthesis,2012,vol. 44,p. 2537 - 2546
  • 61
  • [ 1422045-46-2 ]
  • [ 36600-66-5 ]
  • [ 1422045-58-6 ]
Reference： [1]Chemical Communications,2013,vol. 49,p. 1413 - 1415
  • 62
  • [ 1003909-32-7 ]
  • [ 36600-66-5 ]
  • [ 1422045-54-2 ]
Reference： [1]Chemical Communications,2013,vol. 49,p. 1413 - 1415
  • 63
  • C24H29NO6 [ No CAS ]
  • [ 36600-66-5 ]
  • C27H35N3O5 [ No CAS ]
Reference： [1]RSC Advances,2013,vol. 3,p. 4526 - 4530
  • 64
  • [ 36600-66-5 ]
  • [ 94-41-7 ]
  • [ 161055-61-4 ]
Reference： [1]RSC Advances,2013,vol. 3,p. 15396 - 15403
  • 65
  • [ 36600-66-5 ]
  • [ 94-41-7 ]
  • [ 161055-61-4 ]
  • [ 1456823-43-0 ]
Reference： [1]RSC Advances,2013,vol. 3,p. 15396 - 15403
[2]RSC Advances,2013,vol. 3,p. 15396 - 15403
  • 66
  • [ 36600-66-5 ]
  • [ 94-41-7 ]
  • [ 1456823-43-0 ]
Reference： [1]RSC Advances,2013,vol. 3,p. 15396 - 15403
  • 67
  • [ 21551-47-3 ]
  • [ 36600-66-5 ]
  • [ 1456823-38-3 ]
Reference： [1]RSC Advances,2013,vol. 3,p. 15396 - 15403
  • 68
  • [ 21551-47-3 ]
  • [ 36600-66-5 ]
  • [ 1456823-49-6 ]
Reference： [1]RSC Advances,2013,vol. 3,p. 15396 - 15403
  • 69
  • [ 1221963-20-7 ]
  • [ 36600-66-5 ]
  • [ 1456823-39-4 ]
Reference： [1]RSC Advances,2013,vol. 3,p. 15396 - 15403
  • 70
  • [ 1221963-20-7 ]
  • [ 36600-66-5 ]
  • [ 1456823-50-9 ]
Reference： [1]RSC Advances,2013,vol. 3,p. 15396 - 15403
  • 71
  • [ 6552-62-1 ]
  • [ 36600-66-5 ]
  • [ 1456823-41-8 ]
Reference： [1]RSC Advances,2013,vol. 3,p. 15396 - 15403
  • 72
  • [ 6552-62-1 ]
  • [ 36600-66-5 ]
  • [ 1456823-52-1 ]
Reference： [1]RSC Advances,2013,vol. 3,p. 15396 - 15403
  • 73
  • [ 36600-66-5 ]
  • [ 908303-07-1 ]
  • C26H31NO4 [ No CAS ]
Reference： [1]European Journal of Organic Chemistry,2013,p. 5917 - 5922
  • 74
  • [ 36600-66-5 ]
  • [ 65-85-0 ]
  • N'-(4-(tert-butyl)phenyl)benzohydrazide [ No CAS ]
YieldReaction ConditionsOperation in experiment
65% With 6-chloro-3-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazol-3-ium-1-olatehexafluorophosphate(V); triethylamine; In N,N-dimethyl-formamide; at 20℃; General procedure: To a solution of benzoic acid (610.6mg, 5mmol) and phenylhydrazine hydrochloride (723.0mg, 5mmol) in DMF (10.0mL) was added HCTU (5-Chloro-1-[bis(dimethylamino)methylene]-1H-benzotriazolium 3-oxide hexafluorophosphate) (2275.3mg, 5.5mmol) and Et3N (2085.0mL, 15mmol). The reaction mixture was stirred at room temperature for overnight. Then the reaction mixture was washed with saturated NH4Cl (aq), NaHCO3 (aq) and brine. The organic layer was dried over MgSO4 and the solvent was removed under reduced pressure. The residue was purified by column chromatography to give 1a as a white solid (955.2mg, 90percent).
Reference： [1]Tetrahedron,2015,vol. 71,p. 9073 - 9080
  • 75
  • [ 2960-66-9 ]
  • [ 36600-66-5 ]
  • 5-(1,1-dimethylethyl)-1H-indole-3-acetic acid ethyl ester [ No CAS ]
Reference： [1]Chemistry - A European Journal,2016,vol. 22,p. 2616 - 2619
  • 76
  • [ 2960-66-9 ]
  • [ 36600-66-5 ]
  • (2E,4E)-4-{2-[4-(1,1-dimethylethyl)phenyl]hydrazono}-2-butenoic acid ethyl ester [ No CAS ]
Reference： [1]Chemistry - A European Journal,2016,vol. 22,p. 2616 - 2619
  • 77
  • [ 36600-66-5 ]
  • [ 3788-94-1 ]
  • [ 1225558-43-9 ]
YieldReaction ConditionsOperation in experiment
4.5 g Journal of Chemical Society Perkin Trans I (J. Chem. Soc. Perkin trans. Of I), p. 1875 (ethoxy-methylene-up gave the synthesized 2-to the method described in 1988), ethyl acetoacetate (13.92g) in ethanol (4-tert- butyl phenyl hydrazine in 45) hydrochloride solution (15.0g) adding an aqueous solution (45), and stirred for 4 hours at reflux temperature. After adding water to the reaction liquid, extracted with ethyl acetate, washed with saturated aqueous sodium chloride, and distilled to remove the solvent under reduced pressure. To the residue sodium hydroxide (5.9g), water (45), addition of ethanol (45), and stirred for 2 hours at reflux temperature. After the reaction, the solvent was distilled off, and washed with toluene, and then remove the acidic by addition of dilute hydrochloric acid to the aqueous layer, after extraction with ethyl acetate, dried over anhydrous magnesium sulfate, distilling off the solvent under reduced pressure. By overriding the precipitated solid with ethyl acetate / n- hexane solvents to obtain the title compound (4.50g).
Reference： [1]Patent: KR2015/2661,2015,A .Location in patent: Paragraph 0356; 0357
  • 78
  • [ 34846-90-7 ]
  • [ 36600-66-5 ]
  • 1-(4-tertbutylphenyl)-5-hydroxypyrazole [ No CAS ]
YieldReaction ConditionsOperation in experiment
84.1% In methanol; for 6h;Reflux; To three reaction vials, 20. lg (100 mmol) of <strong>[36600-66-5]4-tert-butylphenylhydrazine hydrochloride</strong>, 11.6 g (100 mmol) of methyl methacrylate, and 1.0 mL of methanol were added. The reaction mixture was heated to reflux for about 6 hours. The reaction solution was quantified by liquid chromatography, and 1- (4-tertButylphenyl) -5-hydroxypyrazole in a yield of 84.1percent.
Reference： [1]Patent: CN104059020,2016,B .Location in patent: Paragraph 0024; 0025
  • 79
  • [ 201230-82-2 ]
  • [ 19820-56-5 ]
  • [ 36600-66-5 ]
  • 2-(4-(tert-butyl)phenyl)phthalazin-1(2H)-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
68% With palladium(II) trifluoroacetate; 1,3-bis-(diphenylphosphino)propane; magnesium sulfate; 1,8-diazabicyclo[5.4.0]undec-7-ene; In acetonitrile; at 150℃; under 7500.75 Torr; for 21h;Autoclave; General procedure: 2-Formylaryl tosylate (2 mmol), hydrazine (2 mmol), Pd(TFA)2 (5 molpercent), dppp (10 molpercent), DBU (2.4 mmol), anhydrous MgSO4 (2 mmol) and CH3CN (30 ml) were charged in a 200 ml-autoclave. The autoclave was flushed using CO three times. The reaction was pressurized with CO to 1.0 MPa, and stirred at 140 °C for 21 h. Then the mixture was cooled to room temperature and the excess CO was vented. Solvent was removed under reduced pressure and the crude residue was purified by column chromatography on silica gel with petroleum ether-ethyl acetate as the eluent to afford the desired product.
Reference： [1]Tetrahedron,2016,vol. 72,p. 8282 - 8286
  • 80
  • [ 110-91-8 ]
  • [ 201230-82-2 ]
  • [ 36600-66-5 ]
  • [ 79868-24-9 ]
YieldReaction ConditionsOperation in experiment
90% With oxygen; palladium diacetate; sodium carbonate; triphenylphosphine; In 1,4-dioxane; dimethylsulfoxide-d6; carbon dioxide; at 100℃; for 12h;Schlenk technique; liquid CO2; To a clean 25 mL Schlenk tube was added 0.4 mmol of <strong>[36600-66-5]4-tert-butylphenylhydrazine hydrochloride</strong> andPd (OAc) 3 (1.3 mg, 3 molpercent), PPh3 (10.5 mg, 20 molpercent), Na2CO3 (21.2 mg, 0.2 mmol)In CO: O2 = 3: 1(17.4 mg, 0.2 mmol) and a mixed solvent(Dmso: dioxane = 0.1: 0.9mL), reaction at 100 for 12h, TLC plate detection;Of morpholine (& lt; RTI ID = 0.0 & gt;2) After completion of the reaction, the reaction solution was added with 2 mL of water and extracted with EA for 3-5 times. The organic layer was concentrated and purifiedColumn chromatography afforded the pure amide compound as a yellow solid in 90percent yield.
Reference： [1]Patent: CN106008125,2016,A .Location in patent: Paragraph 0028; 0029 0030; 0031; 0032
[2]Journal of Organic Chemistry,2017,vol. 82,p. 4970 - 4976
  • 81
  • [ 201230-82-2 ]
  • [ 36600-66-5 ]
  • [ 108-95-2 ]
  • [ 26459-51-8 ]
Reference： [1]Journal of Organic Chemistry,2017,vol. 82,p. 4970 - 4976
  • 82
  • [ 36600-66-5 ]
  • [ 98-53-3 ]
  • 3,6-di-tert-butyl-2,3,4,9-tetrahydro-1H-carbazole [ No CAS ]
YieldReaction ConditionsOperation in experiment
85% With hydrogenchloride; In ethanol; water; for 5h;Reflux; 9-(2-dicyclohexylphosphonophenyl) -3,6-di-tert-butyl-9H-carbazole as shown,The preparation of 9- (2-dicyclohexylphosphonophenyl) -3,6-di-tert-butyl-9H-carbazole is:In a 250 ml round bottom flask,10.0 g of <strong>[36600-66-5]4-tert-butylphenylhydrazine hydrochloride</strong> (60 mmol) was added,Then 8.48 g of 4-tert-butylcyclohexanone (66 mmol) was added,Add 100 ml of ethanol,And then slowly add 5 ml of hydrochloric acid,The mixture was stirred for 5 hours under reflux,After the reaction is completely returned to room temperature,After crystallization, water was collected and washed with water to obtain 14.4 g of 3,6-di-tert-butyl-2,3,4,9-tetrahydro-1H-carbazole,Decompress all the solution,Yield 85percent, can be directly into the next step reaction.
Reference： [1]Patent: CN106588983,2017,A .Location in patent: Paragraph 0109
  • 83
  • [ 201230-82-2 ]
  • [ 36600-66-5 ]
  • [ 536-74-3 ]
  • 1,5-bis(4-(tert-butyl)phenyl)-3-phenyl-1H-pyrazole [ No CAS ]
Reference： [1]Organic Letters,2017,vol. 19,p. 3466 - 3469
  • 84
  • [ 870-50-8 ]
  • [ 35634-10-7 ]
  • [ 36600-66-5 ]
  • di-tert-butyl 1-(3-(4-(tert-butyl)phenyl)bicyclo[1.1.1]pentan-1-yl)hydrazine-1,2-dicarboxylate [ No CAS ]
Reference： [1]Journal of the American Chemical Society,2017,vol. 139,p. 17791 - 17794
  • 85
  • [ 36600-66-5 ]
  • potassium phenyltrifluoborate [ No CAS ]
  • [ 1625-92-9 ]
Reference： [1]Applied Organometallic Chemistry,2018,vol. 32
  • 86
  • [ 696-63-9 ]
  • [ 36600-66-5 ]
  • (4-(tert-butyl)phenyl)(4-methoxyphenyl)sulfane [ No CAS ]
Reference： [1]Journal of Organic Chemistry,2018,vol. 83,p. 2389 - 2394
  • 87
  • [ 33439-27-9 ]
  • [ 36600-66-5 ]
  • 8‐(tert‐butyl)‐2‐tosyl‐2,3,4,5‐tetrahydro‐1H‐pyrido[4,3‐b]indole [ No CAS ]
Reference： [1]Organic Letters,2018,vol. 20,p. 5457 - 5460
  • 88
  • [ 1203549-59-0 ]
  • [ 36600-66-5 ]
  • 3β-acetoxy-17β-[5'-hydroxy-1'-(4"-tert-butylphenyl)-1'H-pyrazol-3'-yl]androst-5-ene [ No CAS ]
YieldReaction ConditionsOperation in experiment
87% With sodium acetate; acetic acid; In ethanol; at 120℃; for 0.166667h;Microwave irradiation; General procedure: Arylhydrazine hydrochloride (5d?j, 1.0 mmol) and NaOAc (82 mg, 1.0 mmol) were dissolved in EtOH (10 mL). The reaction mixture was stirred at 40 °C for 10 min and then compound 4 (333 mg, 0.80 mmol) dissolved in AcOH (20 mL) was added. The reaction mixture was irradiated at 120 °C for a given time (max. power: 150 W) and then poured into cold water (10 mL). The resulting precipitate was filtered and the crude product purified by column chromatography
Reference： [1]Beilstein Journal of Organic Chemistry,2018,vol. 14,p. 2589 - 2596

Tags: 36600-66-5 synthesis path| 36600-66-5 SDS| 36600-66-5 COA| 36600-66-5 purity| 36600-66-5 application| 36600-66-5 NMR| 36600-66-5 COA| 36600-66-5 structure

Same Skeleton Products
Related Products
Categories
Chemistry
Organic Building Blocks
Benzene Compounds
benzyl
Chemistry
Organic Building Blocks
Benzene Compounds
tert-butylbenzene
Chemistry
Organic Building Blocks
Hydrazines
phenylhydrazine
Chemistry
Organic Building Blocks
Aryls
Chemistry
Organic Building Blocks
Amines
Historical Records

Related Functional Groups of
[ 36600-66-5 ]

Aryls

Chemical Structure| 128231-55-0

[ 128231-55-0 ]

(4-(tert-Butyl)phenyl)hydrazine hydrochloride

Similarity: 1.00

Chemical Structure| 306937-27-9

[ 306937-27-9 ]

(3-(tert-Butyl)phenyl)hydrazine hydrochloride

Similarity: 0.97

Chemical Structure| 118427-29-5

[ 118427-29-5 ]

4-Isopropylphenylhydrazine hydrochloride

Similarity: 0.97

Chemical Structure| 61765-93-3

[ 61765-93-3 ]

(4-(tert-Butyl)phenyl)hydrazine

Similarity: 0.97

Chemical Structure| 1030288-67-5

[ 1030288-67-5 ]

(3-Isopropylphenyl)hydrazine hydrochloride

Similarity: 0.93

Amines

Chemical Structure| 128231-55-0

[ 128231-55-0 ]

(4-(tert-Butyl)phenyl)hydrazine hydrochloride

Similarity: 1.00

Chemical Structure| 306937-27-9

[ 306937-27-9 ]

(3-(tert-Butyl)phenyl)hydrazine hydrochloride

Similarity: 0.97

Chemical Structure| 118427-29-5

[ 118427-29-5 ]

4-Isopropylphenylhydrazine hydrochloride

Similarity: 0.97

Chemical Structure| 61765-93-3

[ 61765-93-3 ]

(4-(tert-Butyl)phenyl)hydrazine

Similarity: 0.97

Chemical Structure| 1030288-67-5

[ 1030288-67-5 ]

(3-Isopropylphenyl)hydrazine hydrochloride

Similarity: 0.93

Hydrazines

Chemical Structure| 128231-55-0

[ 128231-55-0 ]

(4-(tert-Butyl)phenyl)hydrazine hydrochloride

Similarity: 1.00

Chemical Structure| 306937-27-9

[ 306937-27-9 ]

(3-(tert-Butyl)phenyl)hydrazine hydrochloride

Similarity: 0.97

Chemical Structure| 118427-29-5

[ 118427-29-5 ]

4-Isopropylphenylhydrazine hydrochloride

Similarity: 0.97

Chemical Structure| 61765-93-3

[ 61765-93-3 ]

(4-(tert-Butyl)phenyl)hydrazine

Similarity: 0.97

Chemical Structure| 1030288-67-5

[ 1030288-67-5 ]

(3-Isopropylphenyl)hydrazine hydrochloride

Similarity: 0.93